ex-u market off-set tougher us
updat sales/gaap ep cc
cc exh
 assum om sale estimate in-lin
consensu report vs abmd sale guidanc
ep also match consensu believ
ex-u impella growth esp japan begin off-set tougher us comp
addit view abmd featur rich impella connect system offer
competit advantag futur entrant dcf base pt remain
updat fy estim updat fy sales/gaap ep
cc cc
exhibit assum om
estim compar consensu
recognit tougher comp us busi base grow
model us impella growth ex-u growth given grow
matur opportun japan germani
impella connect system offer competit advantag believ
impella connect system offer secur continu remot monitor
impella-support patient give signific competit advantag
inevit futur entranc competit product real-tim view
enabl physician remot see live feed impella consol allow
quickli address alert improv patient manag inclus
devic adjust due inadvert impella mechan displac
 patient wean addit data eman system
allow formal key clinic protocol rule govern wean
particularli import applic new geographi ad system
grant abil ensur best practic util
physicians/hospit staff ultim lead improv clinic outcom
increas adopt impella connect system current pilot phase
us hospit compani state begin analyz service-
base model reach site addit press releas
morn announc impella connect receiv ce
tr target
continu pg
growth continu see strong growth germani appear
control launch japan gain traction expect sale fy
believ ex-u opportun help off-set tougher comp continu increas
base busi us fy first quarter abmd om exceed year ahead
long-term target note manag said aim investor day later
plan give updat estim
valuat risk price target dcf base predic explicit model
abmd fy termin year assum corpor revenu ex-
us oper margin assum discount rate termin growth factor
given high oper margin structur compani suffici cash readili avail
technolog acquisit princip risk thesi evid develop adjac
segment ami w/o cs pci acut systol heart failur without cs pci ami may
develop curtail market opportun addit competit encroach may come faster
harder envis final abmd strong valuat reflect long tail opportun
short term miss rel street expect could caus abrupt pull-back
page
page
strh estimatesconsensusstrh vs consensu cc est us us impella impella product statementstrh estimatesabmdconsensusstrh vs consensu cc adjust incl incom incom incom adj estimatesabmdconsensusstrh vs consensusmargin expens margin adjust incl inc
page
strh estimatesstrhconsensusstrh vs consensu cc est us us impella impella product statementstrh estimatesstrhconsensusstrh vs consensu cc adjust incl incom incom incom adj estimatesstrhconsensusstrh vs consensusmargin expens margin adjust incl inc
page
million except impella ou impella revenu total impella product servic total product fund total gross research total oper oper incom total incom expens pre-tax tax paid tax incom ep average share total reconciliations- net incom ep margin margin analysi yoy us impella impella impella revenu impella product impella product revenu revenu revenu oper incom incom abiom inc
 base danver
result proprietari databas analys believ impella-lik devic us
market opportun present larg opportun unlik
measur competit valuat also augment high intrins profit
impella revenu gross margin north rate share buy
valuat risk
price target dcf base predic explicit model abmd fy
termin year assum corpor revenu ex-u oper
margin assum discount rate termin growth factor given high oper
margin structur compani suffici cash readili avail technolog acquisit
princip risk thesi evid develop adjac segment ami w/o cs
pci acut systol heart failur without cs pci ami may develop curtail market
opportun addit competit encroach may come faster harder envis
final abmd strong valuat reflect long tail opportun short term miss rel
street expect could caus abrupt pull-back
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
